Vasopressin Analog Drug Class List

Drugs in Drug Class: Vasopressin Analog

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)	desmopressin acetate	SPRAY, METERED;NASAL	076703-001	Jan 27, 2005	AB	RX	No	Yes
Ubi	DESMOPRESSIN ACETATE	desmopressin acetate	INJECTABLE;INJECTION	210218-001	Feb 14, 2020	AP	RX	No	No
Meitheal	DESMOPRESSIN ACETATE	desmopressin acetate	INJECTABLE;INJECTION	074888-001	Oct 15, 1997	AP	RX	No	No
Abhai Llc	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	210371-002	Jan 28, 2019	AB	RX	No	No

Vasopressin Analog Market Dynamics and Patent Landscape: Key Patents, Exclusivity Timelines, and Generic/Biosimilar Risk

Last updated: June 26, 2026

Executive summary

Vasopressin analogs used in endocrine and urologic indications are dominated by a small set of active ingredients and delivery forms, with patent protection concentrated in: (1) peptide sequence and manufacturing process patents for long-acting formulations, (2) device and delivery-system claims for nasal/oral alternatives, and (3) method-of-use claims tied to diabetes insipidus and related water-balance disorders. The near-to-mid term market dynamics hinge on the staggered loss of exclusivity across individual products and strengths, while generic entry risk is primarily driven by Orange Book-listed patents (where applicable) and Paragraph IV validity/indication-claim strategies. Across the class, the most material entry barriers are formulation- and device-linked exclusivity plus manufacturing process claim scope for peptide lyophilized/long-acting products. Patent estates vary by molecule: some have clear expiration schedules enabling predictable generic launch windows, while others retain “evergreen” protection via secondary patents on formulation, stability, and dosing regimens.

Which vasopressin analog drugs are in the market, and how do they differ in patent exposure?

The “vasopressin analog” class is best treated as multiple product-level patent estates rather than a single monolith. Market exposure depends on (a) whether the marketed product is short-acting vs long-acting, (b) whether it is nasal, injectable, implant, or subcutaneous, and (c) whether the formulation is lyophilized or sustained-release.

H3: Common vasopressin analogs (commercially relevant active ingredients)

• Desmopressin (DDAVP and generics): antidiuretic therapy for central diabetes insipidus and nocturia due to nocturnal polyuria (indication varies by product and geography).
• Vaptans are not vasopressin analogs (they are vasopressin receptor antagonists). Patent dynamics differ materially because they are small molecules, not peptides.

H3: What drives patent exposure in vasopressin analogs

• Peptide sequence and analog claims: typically early-expiring primary patents around the active ingredient/sequence.
• Long-acting and formulation patents: often the main remaining barrier, including:
  • sustained-release matrix/device
  • lyophilization and reconstitution conditions
  • stabilizers, concentrations, and pH/tonicity targets
• Method-of-use and dosing regimen claims: cover specific water-balance targets, titration strategies, or patient subpopulations.
• Manufacturing/process patents: typical in peptide products, covering synthesis steps, purification, and sterile fill processes.

What patents protect desmopressin and other vasopressin analogs, and how strong are the estates?

Patent estates for vasopressin analogs are frequently built from layered filings: composition-of-matter, formulation/process, and secondary method claims. Strength is determined by remaining term, claim survivability against obviousness, and whether Orange Book-listed patents are tightly tied to the exact marketed formulation.

H3: Typical patent families that define exclusivity value

1. Active ingredient or analog peptide composition patents
2. Pharmaceutical composition patents
   • aqueous solutions vs lyophilized
   • specific excipient systems and concentrations
3. Manufacturing process patents
   • synthesis, purification, and crystallization parameters
   • sterile filtration and aseptic processing parameters
4. Device/delivery system claims
   • nasal spray or alternative delivery platforms (where applicable)
5. Method-of-use patents
   • dosing regimens and indication-specific claims

H3: Strength indicators used in litigation and licensing

• Remaining statutory term of the latest controlling patent family.
• Whether Orange Book-listed patents include formulation and/or method-of-use tied to the NDA/BLA.
• Claim construction risk: whether dependent formulation claims are narrow and easy to design around vs broad enough to capture alternatives.
• Whether the patent holder has asserted patents in prior Paragraph IV cases for similar products, which is a proxy for enforceability posture.

When does vasopressin analog exclusivity expire, and what launches are most likely to follow?

Exclusivity is best mapped on a product-by-product basis. The class-wide pattern is a staggered fall-off as individual strengths, dosage forms, and route-specific products have distinct NDA and patent-proxy timelines.

H3: High-level exclusivity timeline mechanics (US)

For most approved drug products, relevant time markers include:

• Patent expiry: composition and secondary patents have different expiration dates.
• Regulatory exclusivity:
  • New Chemical Entity (NCE) is not typically relevant for older peptide actives like desmopressin.
  • Orange Book-listed patents control Paragraph IV timing for generics.
• Market exclusivity vs patent exclusivity: both can delay entry but are product-specific.

H3: Practical launch windows

• Generic and authorized generic opportunities usually cluster around:
  • loss of the last listed patent covering the exact dosage form and strength, and
  • resolution/expiration of any pending Paragraph IV litigation stay or settlement.

What is the Orange Book status of desmopressin products, and which patents are usually listed?

Orange Book status determines Paragraph IV strategy for generics. For peptide products, Orange Book listings often include:

• formulation/ composition patents
• method-of-use patents
• sometimes process patents (depending on listing practices and patent grant status)

H3: Typical Orange Book listing categories for peptide analogs

• Drug substance/active ingredient
• Drug product/formulation
• Method of use (if claims are linked to the approved labeling)

H3: How Orange Book listings impact Paragraph IV risk

A generic challenger must show that the listed patents are:

• invalid,
• unenforceable, or
• will not be infringed by the proposed generic product.

In vasopressin analogs, non-infringement is often the key battlefield, where challengers argue:

• different formulation/excipient system
• different manufacturing process not covered by the claim
• differences in dosing regimen not matching method-of-use claims

How do Paragraph IV challenges affect generic entry for vasopressin analogs?

Paragraph IV filing is the entry lever for small-molecule generics, but peptide analogs show entry friction if patents are formulation- and method-heavy.

H3: Common Paragraph IV dispute themes in vasopressin analog products

• Formulation differences:
  • excipient composition and concentration
  • pH and osmolarity targets
  • stabilizers and antioxidants
• Lyophilized stability claims:
  • manufacturing steps and reconstitution parameters
• Method-of-use labeling:
  • the generic “carves” labeling to avoid infringement, or litigants dispute whether carved labeling still infringes

H3: Settlement-driven dynamics

Where settlements occur, they typically:

• define launch dates for the generic,
• specify whether “at-risk” launch is allowed,
• include royalty or payment terms (scope varies by case),
• and sometimes require agreed labeling carve-outs.

Which companies own the most important vasopressin analog patents, and who is challenging?

Market dynamics are shaped by the patent holder and the generic challengers’ ability to design around listed patents.

H3: Patent holder and challenger patterns (how to read the landscape)

• Patent holders typically include:
  • original innovators and their assignees,
  • formulation-focused specialty pharma licensors.
• Challengers typically include:
  • large Indian and US generic manufacturers (for ANDA filings),
  • smaller specialty entrants where reformulation or device redesign can bypass narrow claims.

What formulation patents protect nasal vs injectable vasopressin analog products?

Delivery-route and dosage form drive most formulation IP.

H3: Nasal spray and device-linked claims

Where products use nasal delivery:

• device interface claims can be significant,
• particle size, spray characteristics, and deposition uniformity can be tied to formulation patents.

H3: Injectable/lyophilized manufacturing claims

For injectable peptides:

• lyophilization cycle parameters
• reconstitution instructions
• shelf-life stability under defined storage conditions are often the core IP barriers.

Do vasopressin analogs face biosimilar-style competition, and what is the biologics risk?

Biosimilars apply to biologics. Most vasopressin analogs used for water-balance disorders are small synthetic peptides. That typically means:

• ANDA generic pathway rather than BLA biosimilar pathway, assuming the product is approved as a chemical (or peptide) drug and not biologic/complex biologic. The key competitor risk remains generic substitution rather than biosimilar litigation dynamics.

How does desmopressin compare with other vasopressin analogs on patent expiry and generic risk?

A comparison lens uses three variables:

1. Number of patent families still active
2. Whether the remaining patents cover formulation/device
3. Whether Orange Book listings are tightly tied to exact dosage form/strength

H3: Comparison matrix (product-level scoring approach)

• Lower generic risk tends to correlate with:
  • narrow, formulation-specific claims
  • fewer carve-out options
  • active litigation or recently issued secondary patents
• Higher generic risk correlates with:
  • last-listed patents near expiry
  • patents that are process-heavy but not easily enforced across manufacturing sites
  • labeling carve-out feasibility

What manufacturing and IP barriers block generic makers for vasopressin analogs?

Even where patents are older, practical barriers can include:

• peptide synthesis reproducibility and impurity profile targets
• formulation stability for long shelf-life
• device equivalence for nasal delivery

H3: How process patents increase “practical infringement”

Generic sponsors can attempt to switch manufacturing routes to avoid process claims, but enforcement often focuses on:

• whether steps fall within claim ranges,
• whether intermediates and purification steps match described embodiments,
• and whether “equivalent” conditions were anticipated by the patent.

What FDA status matters most for vasopressin analogs during generic competition?

Regulatory posture influences launch:

• Whether the product is withdrawn, discontinued, or reformulated.
• Whether generics can rely on bridging studies or need additional bioequivalence work.
• Whether labeling can be carved around method-of-use patents.

H3: Competitive impact of labeling and indication scope

For diabetes insipidus and nocturia products, the ability to align with approved labeling without infringing method-of-use claims determines whether the generic can launch as-written or must submit labeling updates.

Where are revenue exposure points highest across the vasopressin analog class?

Revenue exposure generally concentrates in:

• high-volume desmopressin products,
• strengths with fewer direct competitors,
• long-acting or device-linked formulations where substitution is slower.

H3: Revenue risk framing for investors/licensors

• Exposure rises when the “last listed patent” for a high-volume strength approaches expiration.
• Exposure also rises if the reference product faces supply constraints, allowing a generic to win share even before full patent clarity.

Key Takeaways

• Vasopressin analog market dynamics are driven by staggered, product-specific exclusivity loss, with patent barriers concentrated in formulation, device/delivery, and method-of-use claims.
• Generic entry risk for peptide analogs is primarily an Orange Book-and-labeling exercise, with Paragraph IV strategy hinging on non-infringement via formulation/process differences and labeling carve-outs.
• Long-acting or nasal delivery products show higher practical IP barriers due to device and formulation claim scope and stability requirements.
• Patent estate strength is best assessed by the remaining term of the latest Orange Book-listed patents and the claim survivability against design-around and carve-out arguments.
• Competition is typically generic substitution under ANDA, with biosimilar-style risk usually lower because most vasopressin analogs are synthetic peptides rather than complex biologics.

FAQs

1. How do formulation excipient differences affect non-infringement in desmopressin ANDA Paragraph IV cases?
2. Which dosage forms of desmopressin have the most active secondary patents (lyophilized vs liquid vs nasal)?
3. How do labeling carve-outs change method-of-use infringement risk for vasopressin analogs?
4. What is the typical role of manufacturing process patents in peptide generic litigation compared with composition and method claims?
5. What regulatory changes (withdrawals, reformulations, new strengths) most often reset competition timelines in vasopressin analog markets?

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-06-26).